SLC5A2 and type 2 diabetes mellitus: Canagliflozin 300 mg showed the best efficacy for HbA1c, FPG and weight control.<h4>Conclusion</h4>Bexagliflozin demonstrates comparable efficacy to most SGLT2 inhibitors in T2DM patients, with a relatively prominent benefit in body weight reduction and a similar safety profile.